Apeldoorn, The Netherlands, 3 May 2017
Contrast Agent Makes Early-Stage of Lymph Node Cancer- Metastases Visible
Radboudumc has used Combidex (Ferumoxtran-10) from the Nijmegen company SPL Medical successfully in hundreds of patients; a new investment round for European registration of Combidex.
The Nijmegen-based SPL Medical, a spin-off from Radboudumc, has a unique MRI contrast agent (Combidex) that can detect early-stage cancer metastases in the lymph nodes. The contrast agent has been used at Radboudumc in hundreds of cancer patients. Through new investments by the German pharmaceutical company b.e. imaging GmbH and PPM Oost, SPL Medical wants to finance European registration of Combidex to enable the diagnosis of prostate cancer metastases in the lymph nodes. Later additional indications will follow.
Read more >>
Nijmegen, The Netherlands, 1 June 2016
BE IMAGING GmbH TO INVEST IN SPL MEDICAL B.V.
The venture b.e. imaging GmbH, part of the Bender Gruppe GmbH, located in Baden-Baden, Germany, and SPL Medical B.V., located in Nijmegen, The Netherlands, have signed today an exclusive License and Distribution Agreement for the marketing of Combidex® (Ferumoxtran-10), a contrast-agent for the detection of cancer metastasis in the lymph nodes using MR imaging, in Germany, Switzerland and Austria. In addition b.e. imaging will invest in SPL Medical and will become a shareholder of the Dutch company from today, alongside the Radboud University Medical Center (Radboudumc).
Read more >